



Effective Date:
Monday, February 04, 2019

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, February 04, 2019

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Effective Date:
Monday, February 04, 2019

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
3124B	1-Naphthol, Blood								•
3124SP	1-Naphthol, Serum/Plasma		•	•	•		•	•	
3124U	1-Naphthol, Urine								•
5903H	Amphetamines Confirmation (Qualitative), Hair		•			•			
0980SP	Carbaryl and Metabolite, Serum/Plasma		•	•	•		•	•	
0980U	Carbaryl and Metabolite, Urine								•
0980B	Carbaryl, Blood	•	•	•	•	•	•	•	
8073B	DUID/DRE Panel, Blood (Forensic) (CSA) - IN State Tox Lab			•					
1569B	Diclofenac, Blood		•	•	•			•	
1569SP	Diclofenac, Serum/Plasma		•	•	•			•	
1569U	Diclofenac, Urine								•
2067B	Etodolac, Blood		•	•	•			•	
2067SP	Etodolac, Serum/Plasma		•	•	•			•	
2067U	Etodolac, Urine								•
2082SP	Fenoprofen, Serum/Plasma		•	•	•			•	
2095SP	Flurbiprofen, Serum/Plasma		•	•	•			•	
2095U	Flurbiprofen, Urine								•
52090B	Ibuprofen / Naproxen Confirmation, Blood		•	•	•			•	
52090FL	Ibuprofen / Naproxen Confirmation, Fluid		•		•			•	
52090SP	Ibuprofen / Naproxen Confirmation, Serum/Plasma		•		•			•	
52090TI	Ibuprofen / Naproxen Confirmation, Tissue		•					•	
52090U	Ibuprofen / Naproxen Confirmation, Urine		•	•	•			•	
2390B	Ibuprofen, Blood		•		•			•	
2390FL	Ibuprofen, Fluid		•	•	•			•	
2390SP	Ibuprofen, Serum/Plasma		•	•	•			•	
2390U	Ibuprofen, Urine		•	•	•			•	
2410B	Indomethacin, Blood		•	•	•			•	
2410SP	Indomethacin, Serum/Plasma		•	•	•			•	
2410U	Indomethacin, Urine		•	•	•				
2486B	Ketoprofen, Blood		•	•	•			•	
2486SP	Ketoprofen, Serum/Plasma		•	•	•			•	
2482B	Ketorolac, Blood		•	•	•			•	



Effective Date:
Monday, February 04, 2019

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
2482SP	Ketorolac, Serum/Plasma			•	•	•		•	
2482U	Ketorolac, Urine								•
52421SP	Memantine Confirmation, Serum/Plasma				•				
2581SP	Memantine, Serum/Plasma				•				
3045B	Modafinil / Armodafinil, Blood			•	•	•		•	
3045SP	Modafinil / Armodafinil, Serum/Plasma			•	•	•		•	
3107B	Nabumetone as Metabolite, Blood			•	•	•		•	
3107SP	Nabumetone as Metabolite, Serum/Plasma			•	•	•		•	
3107U	Nabumetone as Metabolite, Urine			•	•				
3122B	Naphthalene and Metabolite, Blood								•
3122SP	Naphthalene and Metabolite, Serum/Plasma			•	•		•	•	
52406B	Naproxen Confirmation, Blood			•	•	•		•	
52406SP	Naproxen Confirmation, Serum/Plasma			•	•			•	
52406U	Naproxen Confirmation, Urine			•	•				
3130B	Naproxen, Blood			•	•	•		•	
3130FL	Naproxen, Fluid			•	•				
3130SP	Naproxen, Serum/Plasma			•	•			•	
3130U	Naproxen, Urine			•	•	•			
3223B	Nonsteroidal Anti-Inflammatory Drug Panel, Blood								•
3223SP	Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma			•	•	•		•	
3223U	Nonsteroidal Anti-Inflammatory Drug Panel, Urine								•
3286B	Oxaprozin, Blood			•	•	•		•	
3286SP	Oxaprozin, Serum/Plasma			•	•	•		•	
52103B	Phenylbutazone and Metabolite Confirmation, Blood			•	•	•	•	•	
52103FL	Phenylbutazone and Metabolite Confirmation, Fluid			•	•		•		
52103SP	Phenylbutazone and Metabolite Confirmation, Serum/Plasma			•	•	•		•	
52103TI	Phenylbutazone and Metabolite Confirmation, Tissue			•			•		
52103U	Phenylbutazone and Metabolite Confirmation, Urine			•	•	•	•		
3700B	Phenylbutazone and Metabolite, Blood			•	•	•	•	•	
3700SP	Phenylbutazone and Metabolite, Serum/Plasma			•	•	•	•	•	



Effective Date:

Monday, February 04, 2019

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
3700U	Phenylbutazone and Metabolite, Urine		•	•	•	•			
3781B	Piroxicam, Blood		•	•	•			•	
3781SP	Piroxicam, Serum/Plasma		•	•	•			•	
3781U	Piroxicam, Urine		•	•	•				
4505B	Tolmetin, Blood		•	•	•			•	
4505SP	Tolmetin, Serum/Plasma		•	•	•			•	



Test Updates

Test Changes

3124SP 1-Naphthol, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
 Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Special Handling) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Reference Comment was changed.
 Units were changed.
 Methods/CPT Codes were changed [LC-MS/MS (82542)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 2 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (82542): 1-Naphthol
 Method (CPT Code)

Compound Name	Units	Reference Comment
1-Naphthol	ng/mL	Occupational exposure to 640 mcg/cubic meter carbaryl during pesticide application resulted in a peak concentration of 500 ng/mL 1-naphthol in serum. The blood to serum ratio is not known for this compound.

5903H Amphetamines Confirmation (Qualitative), Hair

Summary of Changes: Scope of Analysis was changed.
 Order of Reporting was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80326, 80359)]
 Ephedrine / Pseudoephedrine, MDEA and Phentermine were removed.

Scope of Analysis: LC-MS/MS (80326, 80359): Amphetamine, Methamphetamine, MDA, MDMA
 Method (CPT Code) LC-MS/MS (None):

0980SP Carbaryl and Metabolite, Serum/Plasma



Test Updates

Test Changes

Summary of Changes: Specimen Requirements were changed.
 Specimen Requirements (Transport Temperature) were changed.
 Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Special Handling) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Reference Comment was changed.
 Units were changed.
 Methods/CPT Codes were changed [LC-MS/MS (82542)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 1 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (82542): Carbaryl, 1-Naphthol
 Method (CPT Code)

Compound Name	Units	Reference Comment
Carbaryl	ng/mL	Carbaryl is a carbamate insecticide that may produce cholinergic toxicity following ingestion. Fatal concentrations in blood range from 6000 to 27000 ng/mL. Occupational exposure to 640 mcg/cubic meter during pesticide application resulted in a peak serum concentration of 0.1 ng/mL. The blood to serum ratio is not known for this compound.
1-Naphthol	ng/mL	Occupational exposure to 640 mcg/cubic meter carbaryl during pesticide application resulted in a peak concentration of 500 ng/mL 1-naphthol in serum. The blood to serum ratio is not known for this compound.

0980B Carbaryl, Blood



Test Updates

Test Changes

Summary of Changes: Test Name was changed.
 Specimen Requirements were changed.
 Specimen Requirements (Specimen Container) were changed.
 Stability was changed.
 Scope of Analysis was changed.
 Reference Comment was changed.
 Units were changed.
 Methods/CPT Codes were changed [LC-MS/MS (82542)]
 1-Naphthol was removed.

Specimen Requirements: 1 mL Blood
 Transport Temperature: Frozen
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature. Received Refrigerated.
 Stability: Room Temperature: Not Stable
 Refrigerated: 1 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (82542): Carbaryl
 Method (CPT Code)

Compound Name	Units	Reference Comment
Carbaryl	ng/mL	Carbaryl is a carbamate insecticide that may produce cholinergic toxicity following ingestion. Fatal concentrations in blood range from 6000 to 27000 ng/mL. Occupational exposure to 640 mcg/cubic meter during pesticide application resulted in a peak serum concentration of 0.1 ng/mL. The blood to plasma ratio is not known for this compound.

8073B DUID/DRE Panel, Blood (Forensic) (CSA) - IN State Tox Lab

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature.

1569B Diclofenac, Blood



Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Diclofenac
 Method (CPT Code)

Compound Name	Units	Reference Comment
Diclofenac	mcg/mL	During chronic therapy with 150 mg Diclofenac (daily) for treatment of arthritis, peak plasma concentrations ranged from 0.1 - 2.2 mcg/mL with a mean concentration of 0.8 mcg/mL. The blood to plasma ratio is approximately 0.7.

1569SP Diclofenac, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)



Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80329): Diclofenac
Method (CPT Code)

Compound Name	Units	Reference Comment
Diclofenac	mcg/mL	During chronic therapy with 150 mg Diclofenac (daily) for treatment of arthritis, peak plasma concentrations ranged from 0.1 - 2.2 mcg/mL with a mean concentration of 0.8 mcg/mL.

2067B Etodolac, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Etodolac
Method (CPT Code)

Compound Name	Units	Reference Comment
Etodolac	mcg/mL	Mean peak plasma concentration after a single 600 mg oral dose 37 +/- 9 mcg/mL at 80 minutes post dose. The blood to plasma ratio is approximately 0.6.

2067SP Etodolac, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Etodolac
 Method (CPT Code)

Compound Name	Units	Reference Comment
Etodolac	mcg/mL	Mean peak plasma concentration after a single 600 mg oral dose 37 +/- 9 mcg/mL at 80 minutes post dose.

2082SP Fenoprofen, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Special Handling) were changed.
 Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Fenoprofen
 Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Fenoprofen	mcg/mL	Mean peak plasma concentration after a single 600 mg oral dose: 50 mcg/mL at 2 hours post dose.

2095SP Flurbiprofen, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Flurbiprofen
 Method (CPT Code)

Compound Name	Units	Reference Comment
Flurbiprofen	mcg/mL	Mean peak plasma concentration normalized to a 100 mg oral dose: 16 +/- 5 mcg/mL in geriatric patients at approximately 2.2 hours.

52090B Ibuprofen / Naproxen Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Naproxen
 Method (CPT Code) LC-MS/MS (80329): Ibuprofen

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. The blood to plasma ratio is approximately 0.6. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively. The blood to plasma ratio is unknown for this compound.

52090FL Ibuprofen / Naproxen Confirmation, Fluid

Summary of Changes: Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]

Stability: Room Temperature: Undetermined
 Refrigerated: Undetermined
 Frozen (-20 °C): Undetermined

Scope of Analysis: LC-MS/MS (80329): Naproxen
 Method (CPT Code) LC-MS/MS (80329): Ibuprofen

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.

52090SP Ibuprofen / Naproxen Confirmation, Serum/Plasma



Test Updates

Test Changes

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code) LC-MS/MS (80329): Ibuprofen

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.

52090TI Ibuprofen / Naproxen Confirmation, Tissue

Summary of Changes: Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]

Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code) LC-MS/MS (80329): Ibuprofen

Compound Name	Units	Reference Comment
Ibuprofen	mcg/g	This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.

52090U Ibuprofen / Naproxen Confirmation, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Urine
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Naproxen
 Method (CPT Code) LC-MS/MS (80329): Ibuprofen

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.

2390B Ibuprofen, Blood

Summary of Changes: Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Ibuprofen
 Method (CPT Code)

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. The blood to plasma ratio is approximately 0.6. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen

2390FL Ibuprofen, Fluid

Summary of Changes: Specimen Requirements were changed.
 Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]



Effective Date:
Monday, February 04, 2019

Test Updates

Test Changes

Specimen Requirements: 2 mL Fluid
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: Undetermined
 Refrigerated: Undetermined
 Frozen (-20 °C): Undetermined
 Scope of Analysis: LC-MS/MS (80329): Ibuprofen
 Method (CPT Code)

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.

2390SP Ibuprofen, Serum/Plasma

Summary of Changes: Specimen Requirements (Special Handling) were changed.
 Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Ibuprofen
 Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen

2390U Ibuprofen, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Ibuprofen
Method (CPT Code)

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.

2410B Indomethacin, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature.
 Stability: Room Temperature: 2 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Indomethacin
 Method (CPT Code)

Compound Name	Units	Reference Comment
Indomethacin	mcg/mL	Mean peak plasma concentrations at approximately 2 hours are 1 and 2 mcg/mL following single oral doses of 25 and 50 mg, respectively. The blood to plasma ratio is approximately 0.5.

2410SP Indomethacin, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Special Handling) were changed.
 Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 7 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Indomethacin
 Method (CPT Code)

Compound Name	Units	Reference Comment
Indomethacin	mcg/mL	Mean peak plasma concentrations at approximately 2 hours are 1 and 2 mcg/mL following single oral doses of 25 and 50 mg, respectively.



Test Updates

Test Changes

2410U Indomethacin, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Urine
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Indomethacin
 Method (CPT Code)

2486B Ketoprofen, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 7 day(s)
 Scope of Analysis: LC-MS/MS (80329): Ketoprofen
 Method (CPT Code)

Compound Name	Units	Reference Comment
Ketoprofen	mcg/mL	Steady state peak plasma concentrations following 200 mg daily oral dosing averaged 2.4 +/- 1.0 mcg/mL for normal release and 3.4 +/- 1.3 mcg/mL for extended release ketoprofen. The blood to plasma ratio is not known for this compound.



Test Updates

Test Changes

2486SP Ketoprofen, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Ketoprofen
Method (CPT Code)

Compound Name	Units	Reference Comment
Ketoprofen	mcg/mL	Steady state peak plasma concentrations following 200 mg daily oral dosing averaged 2.4 +/- 1.0 mcg/mL for normal release and 3.4 +/- 1.3 mcg/mL for extended release ketoprofen.

2482B Ketorolac, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None



Effective Date:
Monday, February 04, 2019

Test Updates

Test Changes

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Ketorolac
Method (CPT Code)

Compound Name	Units	Reference Comment
Ketorolac	mcg/mL	Mean peak plasma concentration following: daily oral dosing with 40 mg: 0.9 +/- 0.2 mcg/mL single IV 15 mg dose: 2.5 mcg/mL (within 3 min; adults) single IV 30 mg dose: 4.7 mcg/mL (within 3 min; adults) The ratio of whole blood concentration to serum or plasma concentration is approximately 0.5. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ketorolac.

2482SP Ketorolac, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Ketorolac
Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Ketorolac	mcg/mL	Mean peak plasma concentration following: daily oral dosing with 40 mg: 0.9 +/- 0.2 mcg/mL single IV 15 mg dose: 2.5 mcg/mL (within 3 min; adults) single IV 30 mg dose: 4.7 mcg/mL (within 3 min; adults) This test is not chiral specific and cannot distinguish between the R and S enantiomers of ketorolac.

52421SP Memantine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

2581SP Memantine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

3045B Modafinil / Armodafinil, Blood

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80342): Modafinil / Armodafinil
Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Modafinil / Armodafinil	mcg/mL	After 7 daily oral doses of 200 or 600 mg Modafinil: Respective mean peak plasma concentrations 6.4 (+/- 0.7) and 17 (+/- 2.0) mcg/mL Respective mean trough plasma concentrations 1.7 (+/- 0.5) and 4.8 (+/- 0.6) mcg/mL The blood to plasma ratio is not known for this compound. This test is not chiral specific; therefore, Armodafinil and/or Modafinil may be present.

3045SP Modafinil / Armodafinil, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80342): Modafinil / Armodafinil
Method (CPT Code)

Compound Name	Units	Reference Comment
Modafinil / Armodafinil	mcg/mL	After 7 daily oral doses of 200 or 600 mg Modafinil: Respective mean peak plasma concentrations 6.4 (+/- 0.7) and 17 (+/- 2.0) mcg/mL Respective mean trough plasma concentrations 1.7 (+/- 0.5) and 4.8 (+/- 0.6) mcg/mL This test is not chiral specific; therefore, Armodafinil and/or Modafinil may be present.

3107B Nabumetone as Metabolite, Blood



Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): 6-MNA
Method (CPT Code)

Compound Name	Units	Reference Comment
6-MNA	mcg/mL	6-MNA (6-Methoxy-2-Naphthylacetic Acid) is the active metabolite of Nabumetone. Steady-state peak plasma concentrations of 6-MNA following a daily oral regimen of 1000 mg Nabumetone: 32-72 mcg/mL at 5 hours in healthy volunteers 15-100 mcg/mL at 6 hours in elderly patients The blood to plasma ratio is not known for this compound.

3107SP Nabumetone as Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).



Test Updates

Test Changes

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (80329): 6-MNA
Method (CPT Code)

Compound Name	Units	Reference Comment
6-MNA	mcg/mL	6-MNA (6-Methoxy-2-Naphthylacetic Acid) is the active metabolite of Nabumetone. Steady-state peak plasma concentrations of 6-MNA following a daily oral regimen of 1000 mg Nabumetone: 32-72 mcg/mL at 5 hours in healthy volunteers 15-100 mcg/mL at 6 hours in elderly patients

3107U Nabumetone as Metabolite, Urine

Summary of Changes: Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (80329): 6-MNA
Method (CPT Code)

3122SP Naphthalene and Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (84600)]

Specimen Requirements: 3 mL Serum or Plasma

Transport Temperature: Refrigerated

Specimen Container: Lavender top tube (EDTA), Plastic container (preservative-free)

Light Protection: Not Required

Special Handling: Serum: Collect sample in Red top tube

Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.

Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Ensure that container remains tightly sealed.

Rejection Criteria: Polymer gel separation tube (SST or PST).

Scope of Analysis: GC (82542): Naphthalene

Method (CPT Code) LC-MS/MS (84600): 1-Naphthol



Test Updates

Test Changes

Compound Name	Units	Reference Comment
1-Naphthol	ng/mL	Occupational exposure to 640 mcg/cubic meter carbaryl during pesticide application resulted in a peak concentration of 500 ng/mL 1-naphthol in serum. The blood to serum ratio is not known for this compound.

52406B Naproxen Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80330)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80330): Naproxen
Method (CPT Code)

Compound Name	Units	Reference Comment
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively. The blood to plasma ratio is unknown for this compound.

52406SP Naproxen Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80330)]

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80330): Naproxen
Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.

52406U Naproxen Confirmation, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80330)]

Specimen Requirements: 1 mL Urine
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80330): Naproxen
 Method (CPT Code)

3130B Naproxen, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Naproxen
 Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively. The blood to plasma ratio is unknown for this compound.

3130FL Naproxen, Fluid

Summary of Changes: Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): Undetermined

Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code)

3130SP Naproxen, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code)

Compound Name	Units	Reference Comment
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.

3130U Naproxen, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None



Effective Date:
Monday, February 04, 2019

Test Updates

Test Changes

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code)

3223SP Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80331), LC-MS/MS (80331)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80331): Ketorolac, Piroxicam, 6-MNA, Flurbiprofen, Indomethacin,
Method (CPT Code) Diclofenac, Ibuprofen
LC-MS/MS (80331): Tolmetin, Ketoprofen, Naproxen, Oxaprozin, Fenoprofen, Etodolac

Compound Name	Units	Reference Comment
Ketorolac	mcg/mL	Mean peak plasma concentration following: daily oral dosing with 40 mg: 0.9 +/- 0.2 mcg/mL single IV 15 mg dose: 2.5 mcg/mL (within 3 min; adults) single IV 30 mg dose: 4.7 mcg/mL (within 3 min; adults) This test is not chiral specific and cannot distinguish between the R and S enantiomers of ketorolac.
Tolmetin	mcg/mL	Reported steady-state plasma concentrations following a 400 mg dose four times a day averaged 45 mcg/mL (range, 8 - 79 mcg/mL).



Effective Date:
Monday, February 04, 2019

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Ketoprofen	mcg/mL	Steady state peak plasma concentrations following 200 mg daily oral dosing averaged 2.4 +/- 1.0 mcg/mL for normal release and 3.4 +/- 1.3 mcg/mL for extended release ketoprofen.
Piroxicam	mcg/mL	The usual plasma concentration during chronic 20 mg daily oral doses is 3 - 8 mcg/mL.
6-MNA	mcg/mL	6-MNA (6-Methoxy-2-Naphthylacetic Acid) is the active metabolite of Nabumetone. Steady-state peak plasma concentrations of 6-MNA following a daily oral regimen of 1000 mg Nabumetone: 32-72 mcg/mL at 5 hours in healthy volunteers 15-100 mcg/mL at 6 hours in elderly patients
Naproxen	mcg/mL	Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.
Flurbiprofen	mcg/mL	Mean peak plasma concentration normalized to a 100 mg oral dose: 16 +/- 5 mcg/mL in geriatric patients at approximately 2.2 hours.
Oxaprozin	mcg/mL	Single oral doses of 1200 mg oxaprozin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women.
Fenoprofen	mcg/mL	Mean peak plasma concentration after a single 600 mg oral dose: 50 mcg/mL at 2 hours post dose.
Indomethacin	mcg/mL	Mean peak plasma concentrations at approximately 2 hours are 1 and 2 mcg/mL following single oral doses of 25 and 50 mg, respectively.
Diclofenac	mcg/mL	During chronic therapy with 150 mg Diclofenac (daily) for treatment of arthritis, peak plasma concentrations ranged from 0.1 - 2.2 mcg/mL with a mean concentration of 0.8 mcg/mL.
Etodolac	mcg/mL	Mean peak plasma concentration after a single 600 mg oral dose 37 +/- 9 mcg/mL at 80 minutes post dose.



Effective Date:
Monday, February 04, 2019

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Ibuprofen	mcg/mL	Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen

3286B Oxaprozin, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxaprozin
 Method (CPT Code)

Compound Name	Units	Reference Comment
Oxaprozin	mcg/mL	Single oral doses of 1200 mg oxaprozin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women. The blood to plasma ratio is approximately 0.5.

3286SP Oxaprozin, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxaprozin
 Method (CPT Code)

Compound Name	Units	Reference Comment
Oxaprozin	mcg/mL	Single oral doses of 1200 mg oxaprozin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women.

52103B Phenylbutazone and Metabolite Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
 Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Scope of Analysis was changed.
 Order of Reporting was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 2 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature.
 Stability: Room Temperature: 2 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
 Method (CPT Code)



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Oxyphenbutazone	mcg/mL	Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL. The blood to plasma ratio is unknown for this compound.
Phenylbutazone	mcg/mL	Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. The blood to plasma ratio is approximately 0.5. Deaths due to blood dyscrasias have been reported following therapeutic administration.

52103FL Phenylbutazone and Metabolite Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
Method (CPT Code)

52103SP Phenylbutazone and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Special Handling) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 2 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
 Method (CPT Code)

Compound Name	Units	Reference Comment
Oxyphenbutazone	mcg/mL	Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL.
Phenylbutazone	mcg/mL	Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. Deaths due to blood dyscrasias have been reported following therapeutic administration.

52103TI Phenylbutazone and Metabolite Confirmation, Tissue

Summary of Changes: Scope of Analysis was changed.
 Order of Reporting was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
 Method (CPT Code)

52103U Phenylbutazone and Metabolite Confirmation, Urine

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Scope of Analysis was changed.
 Order of Reporting was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]



Test Updates

Test Changes

Specimen Requirements: 1 mL Urine
 Transport Temperature: Frozen
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature. Received Refrigerated.
 Stability: Room Temperature: Not Stable
 Refrigerated: 1 day(s)
 Frozen (-20 °C): 2 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
 Method (CPT Code)

3700B Phenylbutazone and Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.
 Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Scope of Analysis was changed.
 Order of Reporting was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 2 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature.
 Stability: Room Temperature: 2 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
 Method (CPT Code)

Compound Name	Units	Reference Comment
Oxyphenbutazone	mcg/mL	Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL. The blood to plasma ratio is unknown for this compound.



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Phenylbutazone	mcg/mL	Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. The blood to plasma ratio is approximately 0.5. Deaths due to blood dyscrasias have been reported following therapeutic administration.

3700SP Phenylbutazone and Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
Method (CPT Code)

Compound Name	Units	Reference Comment
Oxyphenbutazone	mcg/mL	Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL.
Phenylbutazone	mcg/mL	Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. Deaths due to blood dyscrasias have been reported following therapeutic administration.

3700U Phenylbutazone and Metabolite, Urine



Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Scope of Analysis was changed.
 Order of Reporting was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Urine
 Transport Temperature: Frozen
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature. Received Refrigerated.
 Stability: Room Temperature: Not Stable
 Refrigerated: 1 day(s)
 Frozen (-20 °C): 2 day(s)
 Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
 Method (CPT Code)

3781B Piroxicam, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Piroxicam
 Method (CPT Code)

Compound Name	Units	Reference Comment
Piroxicam	mcg/mL	The usual plasma concentration during chronic 20 mg daily oral doses is 3 - 8 mcg/mL. The blood to plasma ratio is not known for this compound.



Test Updates

Test Changes

3781SP Piroxicam, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Special Handling) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Reference Comment was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)
 Scope of Analysis: LC-MS/MS (80329): Piroxicam
 Method (CPT Code)

Compound Name	Units	Reference Comment
Piroxicam	mcg/mL	The usual plasma concentration during chronic 20 mg daily oral doses is 3 - 8 mcg/mL.

3781U Piroxicam, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
 Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Urine
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 15 day(s)
 Refrigerated: 15 day(s)
 Frozen (-20 °C): 15 day(s)



Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80329): Piroxicam
Method (CPT Code)

4505B Tolmetin, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Tolmetin
Method (CPT Code)

Compound Name	Units	Reference Comment
Tolmetin	mcg/mL	Reported steady-state plasma concentrations following a 400 mg dose four times a day averaged 45 mcg/mL (range, 8 - 79 mcg/mL). The blood to plasma ratio is approximately 0.5.

4505SP Tolmetin, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]



Effective Date:
Monday, February 04, 2019

Test Updates

Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Tolmetin
Method (CPT Code)

Compound Name	Units	Reference Comment
Tolmetin	mcg/mL	Reported steady-state plasma concentrations following a 400 mg dose four times a day averaged 45 mcg/mL (range, 8 - 79 mcg/mL).



Effective Date:
Monday, February 04, 2019

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
3124B	1-Naphthol, Blood	3124SP - 1-Naphthol, Serum/Plasma
3124U	1-Naphthol, Urine	3124SP - 1-Naphthol, Serum/Plasma
0980U	Carbaryl and Metabolite, Urine	3124SP - 1-Naphthol, Serum/Plasma
1569U	Diclofenac, Urine	1569SP - Diclofenac, Serum/Plasma
2067U	Etodolac, Urine	2067SP - Etodolac, Serum/Plasma
2095U	Flurbiprofen, Urine	2095SP - Flurbiprofen, Serum/Plasma
2482U	Ketorolac, Urine	2482SP - Ketorolac, Serum/Plasma
3122B	Naphthalene and Metabolite, Blood	3122SP - Naphthalene and Metabolite, Serum/Plasma
3223B	Nonsteroidal Anti-Inflammatory Drug Panel, Blood	3223SP - Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma
3223U	Nonsteroidal Anti-Inflammatory Drug Panel, Urine	3223SP - Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma